S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Phreesia Stock Slides as Earnings Fall Short of Wall Street Targets

A 7.9% drop in share price followed Phreesia’s second-quarter fiscal report, as the healthcare technology firm missed analyst profit expectations by six cents per share. The stock closed Thursday at $10.94, marking a significant decline for a company that has already shed roughly one-third of its market value this year.

Phreesia Stock Slides as Earnings Fall Short of Wall Street Targets

The company posted a profit of $1.9 million for the three months ending July 31, an improvement over the $654,000 reported in the same period last year. Despite this growth, the three-cent-per-share result disappointed investors who anticipated nine cents. Total revenue hit $129.5 million, a 10% increase that matched analyst projections.

Financial results were hampered by a $2.8 million charge related to an ongoing restructuring effort. This plan, intended to trim operating expenses and refine cost structures, is expected to incur total charges of $10 million by the end of fiscal 2027. Chief Executive Chaim Indig defended the performance, citing that revenue and profit expansion tracked with internal expectations. He remains focused on the integration of AccessOne and ProviderConnect, alongside new artificial intelligence investments, to drive future momentum. Looking ahead, Phreesia maintained its full-year guidance, projecting adjusted Ebitda between $125 million and $135 million on revenue reaching up to $520 million.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!